Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
This small retrospective study analyzed the efficacy and safety of rituximab in adults with steroid-dependent minimal change disease. Of the seventeen relapsing steroid-dependent patients treated with rituximab, eleven had no relapses with nine being able to come off all other drugs during the mean 29.5 month follow-up period. This sets the stage for a prospective randomized controlled trial.
- Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
- A Randomized Trial to Assess the Impact of Early Steroid Withdrawal on Growth in Pediatric Renal Transplantation: The TWIST Study
- Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study